MedAssets upgraded to Outperform from Market Perform at Leerink Leerink upgraded MedAssets to Outperform citing the pullback in shares since the Q2 results, the potential for improving volumes in Q3 and the company's total portfolio approach. The firm has a $26 price target for shares.
Healthways, MedAssets partner in new five-year agreement Healthways (HWAY) has partnered with MedAssets (MDAS) to expand patient access to the Dr. Dean Ornish Program for Reversing Heart Disease. Under the five-year agreement, Healthways has contracted with MedAssets as its sales partner to accelerate deployment of the Ornish Reversal Program to hospitals, health systems and physician organizations. The Ornish Reversal Program is the most scientifically proven platform in lifestyle medicine for treating and reversing heart disease and other chronic conditions.